Daratumumab

• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa… Ended
  2023-503441-55-00 Phase II 10 countries Janssen - Cilag International
• MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended
  2023-509208-14-00 Phase III 13 countries Pfizer Inc.
• Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-D… Ended
  2024-517761-17-00 Phase II 1 country University Of Cologne
• A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Ended
  2023-503439-16-00 Phase I/II 1 country Janssen - Cilag International
• A Randomized Study Comparing JNJ-68284528 versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexametha… Ended
  2023-506588-32-00 Phase III 10 countries Janssen - Cilag International
• Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended
  2023-510537-28-00 Phase III 9 countries Glaxosmithkline Research & Development Limited
• Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended
  2024-514963-24-00 Phase II 2 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma Ended
  2023-506587-13-00 Phase II 5 countries Janssen - Cilag International
• A Phase 3 Study Comparing Lenalidomide and Daratumumab Subcutaneous Injection (R-Dara SC) vs Lenalidomide and Dexamethasone (Rd) in Frail Su… Ended
  2024-514088-25-00 Phase III 2 countries Centre Hospitalier Universitaire De Lille
• CC-92480-MM-002 A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Prel… Ended
  2023-505219-19-00 Phase I/II 6 countries Celgene Corp.
• A Trial for relapsed and relapsed/refractory multiple myeloma patients Ended
  2023-506733-30-00 Phase II 1 country Fondazione European Myeloma Network Italy O.N.L.U.S.
• A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended
  2024-511781-37-00 Phase II 3 countries Ceska Myelomova Skupina z.s.; Emn Trial Office S.r.l. Impresa Sociale; European …
• A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended
  2023-506125-10-00 Phase III 11 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended
  2024-516905-22-00 Phase III 1 country Fundacion PETHEMA
• STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (Dara-VM… Ended
  2024-512049-17-00 Phase IV 1 country Universita' Degli Studi Di Torino
• Multicenter, Dose-Escalation and Expansion Study of Combination Therapy with Venetoclax, Daratumumab and Dexamethasone (with and without Bor… Ended
  2023-506110-43-00 Phase I/II 3 countries AbbVie Deutschland GmbH & Co. KG
• A study to decide what is the highest dose of CC-220 to take alone and with other standard of care treatments to assess the side effects, ef… Ended
  2024-510799-19-00 Phase I/II 5 countries Celgene Corp.
• Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells f… Ended
  2024-516908-42-00 Phase II 1 country Fundacion PETHEMA
• Phase II Open-Label, Single Arm, Multicenter Study of Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma Halted
  2023-510560-12-00 Phase II 1 country Fundacion Pethema
• A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended
  2023-503689-21-00 Phase I/II 5 countries F. Hoffmann-La Roche AG
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended
  2024-510590-14-00 Phase III 1 country University Medical Center Hamburg-Eppendorf
• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended
  2023-507086-26-00 Phase I (FiH) 7 countries Genmab A/S
• A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with … Ended
  2023-509848-10-00 Phase III 7 countries Celgene Corp.
• A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamet… Ended
  2023-507312-13-00 Phase III 6 countries Janssen - Cilag International

Showing 49–72 of 77 trials